Interventions: Other: Assessment of executive functions and attention; Other: Evaluation on a driving simulator; Other: Evaluation on-road
Sponsors: Hopital La Musse; French Road Safety Delegation
Not yet recruiting
Nature Neuroscience, Published online: 04 June 2026; doi:10.1038/s41593-026-02338-5
Androgens — hormones that are generally present at higher levels in males than females — regulate intestinal transit, but their cellular targets and mechanisms of action are unclear. We identify the neurons that mediate androgen-dependent gut motility and reveal that androgen reactivation by a bacterial enzyme in the gut lumen is necessary for this vital neuroendocrine axis.
Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an antibody treatment that has shown great promise in animal testing but hasn’t yet undergone a clinical trial to show whether it is efficacious in people, the Department of Health and Human Services confirmed Thursday.
The antibody treatment, known as MBP-134, is made by San Diego-based Mapp Biopharmaceuticals, with funding from the Biomedical Advanced Research and Development Authority, an agency within HHS that helps develop medical countermeasures for rare and emerging diseases, and biological threats.
WASHINGTON — Leaders at the Food and Drug Administration on Thursday listened to criticisms and recommendations for how to move forward with a speedy drug review program put in place by former FDA commissioner Marty Makary.
The listening session, held on the FDA’s White Oak Campus, featured 17 speakers representing patient groups, drug companies, and academic organizations. Some had positive feedback, particularly those whose drugs have already been approved through the program. But most asked the agency to pause the program, and then bring it back through normal regulatory procedures that require public feedback.
Makary launched the Commissioner’s National Priority Voucher program about a year ago, offering one- to two-month FDA reviews to companies that could prove their drugs “align with national priorities.” The priorities, which included addressing health crises and delivering innovative cures, were vague. Critics worried the process was vulnerable to political interference.